Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 69 | 2024 | 21017 | 4.240 |
Why?
|
Sentinel Lymph Node Biopsy | 10 | 2024 | 733 | 3.660 |
Why?
|
Axilla | 18 | 2024 | 626 | 2.830 |
Why?
|
Neoadjuvant Therapy | 15 | 2024 | 2821 | 2.820 |
Why?
|
Mastectomy | 17 | 2021 | 1832 | 2.610 |
Why?
|
Lymph Node Excision | 13 | 2024 | 1303 | 2.220 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 12 | 2020 | 936 | 2.180 |
Why?
|
Carcinoma, Ductal, Breast | 9 | 2020 | 1096 | 1.730 |
Why?
|
Mastectomy, Segmental | 10 | 2022 | 972 | 1.700 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2024 | 3527 | 1.380 |
Why?
|
Lymph Nodes | 11 | 2024 | 3485 | 1.100 |
Why?
|
Malpractice | 2 | 2021 | 555 | 1.070 |
Why?
|
Carcinoma, Lobular | 3 | 2018 | 489 | 0.920 |
Why?
|
Mammaplasty | 3 | 2019 | 1239 | 0.690 |
Why?
|
Breast | 7 | 2023 | 1963 | 0.690 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9273 | 0.670 |
Why?
|
Professional Competence | 2 | 2016 | 431 | 0.670 |
Why?
|
Lymphatic Metastasis | 7 | 2024 | 2943 | 0.650 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 11709 | 0.650 |
Why?
|
Breast Diseases | 1 | 2020 | 443 | 0.570 |
Why?
|
Lymphedema | 5 | 2023 | 524 | 0.570 |
Why?
|
Lymphatic Vessels | 4 | 2022 | 358 | 0.530 |
Why?
|
Education, Nursing, Continuing | 1 | 2015 | 70 | 0.500 |
Why?
|
Patient Care Team | 2 | 2016 | 2504 | 0.490 |
Why?
|
General Surgery | 5 | 2009 | 1677 | 0.490 |
Why?
|
Personal Satisfaction | 1 | 2019 | 641 | 0.480 |
Why?
|
Interprofessional Relations | 3 | 2016 | 989 | 0.480 |
Why?
|
Female | 73 | 2024 | 390316 | 0.470 |
Why?
|
Burnout, Professional | 2 | 2021 | 701 | 0.460 |
Why?
|
Medical Oncology | 4 | 2021 | 2312 | 0.460 |
Why?
|
Cooperative Behavior | 3 | 2016 | 1501 | 0.450 |
Why?
|
Humans | 95 | 2024 | 758381 | 0.420 |
Why?
|
Models, Psychological | 1 | 2016 | 830 | 0.410 |
Why?
|
Patient Education as Topic | 2 | 2024 | 2307 | 0.400 |
Why?
|
Quality Assurance, Health Care | 4 | 2016 | 2167 | 0.380 |
Why?
|
Neoplasms | 8 | 2021 | 22030 | 0.370 |
Why?
|
Societies, Medical | 4 | 2019 | 3891 | 0.360 |
Why?
|
Mammography | 6 | 2017 | 2427 | 0.350 |
Why?
|
Income | 1 | 2019 | 1872 | 0.350 |
Why?
|
Neoplasm Invasiveness | 6 | 2020 | 3617 | 0.340 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2551 | 0.340 |
Why?
|
Patient-Centered Care | 2 | 2016 | 1415 | 0.330 |
Why?
|
Early Detection of Cancer | 7 | 2017 | 3211 | 0.330 |
Why?
|
Neoplasm Staging | 8 | 2017 | 11152 | 0.300 |
Why?
|
Retrospective Studies | 19 | 2023 | 80170 | 0.300 |
Why?
|
Receptors, Estrogen | 4 | 2021 | 2211 | 0.300 |
Why?
|
Middle Aged | 39 | 2024 | 219560 | 0.290 |
Why?
|
Insurance Coverage | 1 | 2019 | 1933 | 0.290 |
Why?
|
Education, Medical, Undergraduate | 1 | 2016 | 1066 | 0.280 |
Why?
|
Biopsy, Needle | 1 | 2012 | 1630 | 0.280 |
Why?
|
Aged | 33 | 2024 | 168217 | 0.280 |
Why?
|
Motivation | 1 | 2016 | 1996 | 0.270 |
Why?
|
Decision Making | 2 | 2017 | 3915 | 0.250 |
Why?
|
Adult | 32 | 2024 | 219916 | 0.250 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2009 | 496 | 0.250 |
Why?
|
Clinical Competence | 3 | 2016 | 4775 | 0.250 |
Why?
|
Biopsy | 2 | 2014 | 6768 | 0.240 |
Why?
|
Patient Readmission | 1 | 2019 | 3261 | 0.240 |
Why?
|
Databases, Factual | 6 | 2020 | 7980 | 0.240 |
Why?
|
Mastectomy, Simple | 2 | 2013 | 23 | 0.230 |
Why?
|
Quality of Health Care | 3 | 2018 | 4317 | 0.220 |
Why?
|
Patient Discharge | 1 | 2016 | 3433 | 0.220 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1797 | 0.220 |
Why?
|
Preoperative Care | 1 | 2012 | 2249 | 0.220 |
Why?
|
Health Care Costs | 2 | 2015 | 3245 | 0.210 |
Why?
|
Vermont | 5 | 2018 | 83 | 0.210 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8530 | 0.210 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9405 | 0.210 |
Why?
|
United States | 20 | 2021 | 72140 | 0.210 |
Why?
|
Models, Biological | 2 | 2018 | 9461 | 0.200 |
Why?
|
Quality of Life | 4 | 2019 | 13286 | 0.200 |
Why?
|
Quality Improvement | 3 | 2014 | 3806 | 0.200 |
Why?
|
Sepsis | 1 | 2015 | 2587 | 0.190 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3526 | 0.190 |
Why?
|
Aged, 80 and over | 11 | 2021 | 58681 | 0.190 |
Why?
|
Receptor, erbB-2 | 3 | 2021 | 2553 | 0.180 |
Why?
|
Internship and Residency | 3 | 2009 | 5865 | 0.170 |
Why?
|
Mass Screening | 4 | 2021 | 5425 | 0.170 |
Why?
|
Attitude of Health Personnel | 3 | 2009 | 3867 | 0.170 |
Why?
|
Referral and Consultation | 2 | 2023 | 3586 | 0.160 |
Why?
|
Workload | 2 | 2019 | 847 | 0.160 |
Why?
|
Guideline Adherence | 3 | 2015 | 2215 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5331 | 0.150 |
Why?
|
Precancerous Conditions | 1 | 2005 | 977 | 0.150 |
Why?
|
Communication | 3 | 2024 | 3846 | 0.150 |
Why?
|
Leadership | 1 | 2007 | 1371 | 0.150 |
Why?
|
Coloring Agents | 2 | 2019 | 560 | 0.150 |
Why?
|
Age of Onset | 1 | 2004 | 3298 | 0.150 |
Why?
|
Accreditation | 1 | 2020 | 473 | 0.140 |
Why?
|
Treatment Outcome | 11 | 2021 | 64379 | 0.140 |
Why?
|
Pancreatic Neoplasms | 2 | 2005 | 5349 | 0.140 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2016 | 63 | 0.140 |
Why?
|
Microsurgery | 2 | 2019 | 796 | 0.140 |
Why?
|
Patient Selection | 3 | 2018 | 4244 | 0.140 |
Why?
|
Receptors, Progesterone | 2 | 2018 | 1130 | 0.130 |
Why?
|
Physicians | 2 | 2016 | 4581 | 0.130 |
Why?
|
Survival Rate | 3 | 2018 | 12721 | 0.130 |
Why?
|
Health Literacy | 1 | 2021 | 441 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2020 | 509 | 0.130 |
Why?
|
Young Adult | 7 | 2020 | 58808 | 0.120 |
Why?
|
Melanoma | 1 | 2014 | 5691 | 0.120 |
Why?
|
Happiness | 1 | 2016 | 170 | 0.120 |
Why?
|
Logistic Models | 2 | 2020 | 13276 | 0.120 |
Why?
|
New England | 1 | 2017 | 1053 | 0.120 |
Why?
|
Prognosis | 5 | 2018 | 29558 | 0.120 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5797 | 0.120 |
Why?
|
Health Behavior | 2 | 2016 | 2615 | 0.110 |
Why?
|
Antineoplastic Protocols | 1 | 2014 | 49 | 0.110 |
Why?
|
Genomics | 2 | 2021 | 5789 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39060 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 622 | 0.110 |
Why?
|
Area Under Curve | 1 | 2018 | 1632 | 0.110 |
Why?
|
Medically Uninsured | 1 | 2019 | 836 | 0.110 |
Why?
|
Neoplasm Metastasis | 5 | 2016 | 4901 | 0.110 |
Why?
|
Ultrasonography, Doppler | 1 | 2015 | 463 | 0.110 |
Why?
|
Age Factors | 4 | 2018 | 18357 | 0.100 |
Why?
|
Risk Factors | 8 | 2021 | 73806 | 0.100 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2013 | 124 | 0.100 |
Why?
|
Collagen | 1 | 2020 | 2635 | 0.100 |
Why?
|
Radiotherapy | 2 | 2018 | 1504 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 921 | 0.100 |
Why?
|
Anesthesiology | 1 | 2022 | 1114 | 0.100 |
Why?
|
Eosinophils | 1 | 2016 | 946 | 0.090 |
Why?
|
Aftercare | 1 | 2016 | 910 | 0.090 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5403 | 0.090 |
Why?
|
Pathology, Surgical | 1 | 2011 | 151 | 0.090 |
Why?
|
Cohort Studies | 5 | 2020 | 41252 | 0.090 |
Why?
|
ROC Curve | 1 | 2018 | 3563 | 0.090 |
Why?
|
Postoperative Care | 1 | 2015 | 1471 | 0.080 |
Why?
|
Practice Guidelines as Topic | 4 | 2015 | 7377 | 0.080 |
Why?
|
Documentation | 1 | 2015 | 892 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2016 | 2675 | 0.080 |
Why?
|
International Educational Exchange | 1 | 2008 | 49 | 0.080 |
Why?
|
Teaching | 1 | 2016 | 1168 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6493 | 0.080 |
Why?
|
Internet | 3 | 2021 | 3082 | 0.070 |
Why?
|
Program Evaluation | 1 | 2016 | 2490 | 0.070 |
Why?
|
Breast Neoplasms, Male | 1 | 2009 | 221 | 0.070 |
Why?
|
Anastomosis, Surgical | 2 | 2022 | 983 | 0.070 |
Why?
|
Attitude to Health | 1 | 2016 | 2025 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2004 | 6313 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15225 | 0.070 |
Why?
|
Forecasting | 2 | 2007 | 2920 | 0.070 |
Why?
|
Survival Analysis | 2 | 2018 | 10112 | 0.070 |
Why?
|
Antineoplastic Agents | 4 | 2016 | 13591 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5484 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2005 | 17768 | 0.070 |
Why?
|
Male | 13 | 2019 | 358742 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2009 | 3425 | 0.070 |
Why?
|
Adolescent | 4 | 2020 | 87888 | 0.070 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20052 | 0.070 |
Why?
|
Medical Records | 1 | 2011 | 1406 | 0.070 |
Why?
|
Efficiency | 1 | 2009 | 477 | 0.060 |
Why?
|
Medicaid | 1 | 2019 | 2807 | 0.060 |
Why?
|
Community-Institutional Relations | 1 | 2007 | 208 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2021 | 4457 | 0.060 |
Why?
|
Hospitals | 1 | 2019 | 3888 | 0.060 |
Why?
|
Reoperation | 2 | 2015 | 4282 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7817 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2751 | 0.060 |
Why?
|
Work Schedule Tolerance | 1 | 2009 | 551 | 0.060 |
Why?
|
Comorbidity | 1 | 2019 | 10495 | 0.060 |
Why?
|
Genetic Testing | 1 | 2017 | 3530 | 0.060 |
Why?
|
Inflammation | 2 | 2015 | 10719 | 0.060 |
Why?
|
Mesothelioma | 1 | 2010 | 807 | 0.060 |
Why?
|
Doxorubicin | 1 | 2010 | 2209 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2476 | 0.050 |
Why?
|
Pilot Projects | 1 | 2016 | 8554 | 0.050 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2005 | 277 | 0.050 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 506 | 0.050 |
Why?
|
Endosonography | 1 | 2005 | 607 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3599 | 0.050 |
Why?
|
Carcinoma | 1 | 2012 | 2330 | 0.040 |
Why?
|
Electronics | 1 | 2022 | 315 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2017 | 4761 | 0.040 |
Why?
|
Axillary Vein | 1 | 2019 | 14 | 0.040 |
Why?
|
Rosaniline Dyes | 1 | 2019 | 48 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6457 | 0.040 |
Why?
|
Fluorescein-5-isothiocyanate | 1 | 2019 | 222 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20500 | 0.040 |
Why?
|
Qualitative Research | 2 | 2021 | 2976 | 0.040 |
Why?
|
Health Care Reform | 1 | 2007 | 1245 | 0.040 |
Why?
|
Veins | 1 | 2022 | 765 | 0.040 |
Why?
|
Peritoneal Neoplasms | 1 | 2004 | 707 | 0.040 |
Why?
|
Age Distribution | 2 | 2014 | 2882 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2021 | 539 | 0.040 |
Why?
|
Europe | 2 | 2014 | 3420 | 0.040 |
Why?
|
Arm | 1 | 2019 | 583 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 15638 | 0.030 |
Why?
|
Comprehension | 1 | 2021 | 619 | 0.030 |
Why?
|
Soft Tissue Neoplasms | 1 | 2004 | 1152 | 0.030 |
Why?
|
Disease Progression | 3 | 2017 | 13468 | 0.030 |
Why?
|
Curriculum | 1 | 2008 | 3717 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 25953 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2022 | 1165 | 0.030 |
Why?
|
Leg | 1 | 2019 | 1087 | 0.030 |
Why?
|
Goals | 1 | 2019 | 707 | 0.030 |
Why?
|
Upper Extremity | 1 | 2019 | 661 | 0.030 |
Why?
|
Lower Extremity | 1 | 2022 | 1188 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 39873 | 0.030 |
Why?
|
International Agencies | 1 | 2014 | 243 | 0.030 |
Why?
|
Sarcoma | 1 | 2004 | 1785 | 0.030 |
Why?
|
Chronic Disease | 2 | 2019 | 9266 | 0.030 |
Why?
|
Pathology | 1 | 2015 | 270 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1067 | 0.030 |
Why?
|
Minority Groups | 1 | 2019 | 1206 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2022 | 1996 | 0.020 |
Why?
|
Incidence | 2 | 2021 | 21273 | 0.020 |
Why?
|
Language | 1 | 2021 | 1532 | 0.020 |
Why?
|
Remission Induction | 1 | 2017 | 2388 | 0.020 |
Why?
|
Registries | 2 | 2020 | 8176 | 0.020 |
Why?
|
Social Support | 1 | 2021 | 2153 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2013 | 631 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1722 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 1791 | 0.020 |
Why?
|
Health Planning | 1 | 2012 | 231 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1530 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 1007 | 0.020 |
Why?
|
Japan | 1 | 2014 | 1366 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12096 | 0.020 |
Why?
|
Prospective Studies | 1 | 2014 | 54136 | 0.020 |
Why?
|
Palliative Care | 1 | 2004 | 3570 | 0.020 |
Why?
|
Carcinoma, Ductal | 1 | 2009 | 97 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6127 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36285 | 0.020 |
Why?
|
Smoking | 1 | 2004 | 9042 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3311 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1893 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2010 | 1539 | 0.020 |
Why?
|
Medically Underserved Area | 1 | 2008 | 257 | 0.020 |
Why?
|
Lung | 1 | 2005 | 9985 | 0.020 |
Why?
|
Drug Carriers | 1 | 2010 | 705 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3242 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2015 | 18125 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1969 | 0.010 |
Why?
|
Acute Disease | 1 | 2015 | 7225 | 0.010 |
Why?
|
Data Collection | 1 | 2013 | 3322 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1793 | 0.010 |
Why?
|
Carcinoma in Situ | 1 | 2009 | 796 | 0.010 |
Why?
|
Pain, Intractable | 1 | 2004 | 132 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3840 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3208 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14641 | 0.010 |
Why?
|
Terminally Ill | 1 | 2004 | 240 | 0.010 |
Why?
|
Mice | 3 | 2015 | 81107 | 0.010 |
Why?
|
Macrophages | 1 | 2016 | 5737 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6068 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8611 | 0.010 |
Why?
|
Posture | 1 | 2005 | 953 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9518 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9650 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10417 | 0.010 |
Why?
|
Risk Assessment | 2 | 2014 | 23883 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 2005 | 1296 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2009 | 5199 | 0.010 |
Why?
|
Animals | 3 | 2015 | 167777 | 0.010 |
Why?
|
Lung Diseases | 1 | 2005 | 1910 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13245 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2004 | 10146 | 0.000 |
Why?
|
Concepts
(259)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_